Renal Damage fm Covid Vaccine; New Zealand Study. 2023-01-28. Jorma Jyrkkanen Blog Post

Acute kidney injury after COVID-19 vaccines: a real-world study Ren Fail. 2022; 44(1): 958–965. Published online 2022 Jun 9. doi: 10.1080/0886022X.2022.2081180 PMCID: PMC9196826 PMID: 35678258 Acute kidney injury after COVID-19 vaccines: a real-world study Huiting Luo,a Xiaolin Li,b Qidong Ren,a Yangzhong Zhou,a Gang Chen,a Bin Zhao,c and Xuemei Lia Author information Copyright and License information Disclaimer Associated Data Data Availability Statement Go to: Abstract Background Acute kidney injury (AKI), a rare adverse event, cannot be ignored as millions of doses of coronavirus disease 2019 (COVID-19) vaccinations. We aimed to investigate the occurrence of post-vaccine AKI reported to the Vaccine Adverse Event Reporting System (VAERS). Methods After data mapping from December 2020 to June 2021, we summarized demographic and clinical features and outcomes of reported cases from three vaccines (Pfizer-BNT, MODERNA, and JANSSEN). The Bayesian and nonproportional analyses explored the correlations between COVID-19 vaccines and AKI. Results We identified 1133 AKI cases. Pfizer-BNT appeared to have a stronger AKI correlation than MODERNA and JANSSEN, based on the highest reporting odds ratio (ROR = 2.15, 95% confidence interval = 1.97, 2.36). We observed the differences in ages, comorbidities, current illnesses, post-vaccine AKI causes, and time to AKI onset (all p＜.05) among three vaccines. Most patients are elderly, with the highest age in MODERNA (68.41 years) and lowest in JANSSEN (59.75 years). Comorbidities were noticed in 58.83% of the cases and active infections in over 20% of cases. The leading cause of post-vaccine AKI was volume depletion (40.78%), followed by sepsis (11.74%). Patients in Pfizer-BNT had the worst outcome with 19.78% deaths, following 17.78% in MODERNA and 12.36% in JANSSEN (p = .217). The proportion of patients on dialysis was higher in JANSSEN than in Pfizer-BNT and MODERNA (14.61% vs. 6.54%, 10.62%, p = .008). Conclusion AKI could occur after the COVID-19 vaccines, predominantly in elderly patients. However, the causality needs further identification. Keywords: COVID-19, vaccination, acute kidney injury, VAERS database Luo H, Li X, Ren Q, Zhou Y, Chen G, Zhao B, Li X. Acute kidney injury after COVID-19 vaccines: a real-world study. Ren Fail. 2022 Dec;44(1):958-965. doi: 10.1080/0886022X.2022.2081180. PMID: 35678258; PMCID: PMC9196826. SEE RELATED Full text links full text provider logo Actions Share Page navigation Title & authors Abstract Conflict of interest statement Figures Similar articles References LinkOut - more resources Front Pharmacol . 2022 Nov 7;13:921760. doi: 10.3389/fphar.2022.921760. eCollection 2022. Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS Ming-Ming Yan 1 , Hui Zhao 1 , Zi-Ran Li 1 , Jun-Wei Chow 1 2 , Qian Zhang 1 , Yu-Peng Qi 1 , Shu-Shan Wu 3 , Ming-Kang Zhong 1 , Xiao-Yan Qiu 1 Affiliations PMID: 36419624 PMCID: PMC9676979 DOI: 10.3389/fphar.2022.921760 Free PMC article Abstract Background and purpose: Serious adverse events following immunization (AEFI) associated with the COVID-19 vaccines, including BNT162b2 (Pfizer-BioNTech), Ad26.COV2.S (Janssen), and mRNA-1273 (Moderna), have not yet been fully investigated. This study was designed to evaluate the serious AEFI associated with these three vaccines. Methods: A disproportionality study was performed to analyze data acquired from the Vaccine Adverse Event-Reporting System (VAERS) between 1 January 2010 and 30 April 2021. The reporting odds ratio (ROR) method was used to identify the association between the COVID-19 vaccines BNT162b2, Ad26.COV2.S, and mRNA-1273 and each adverse event reported. Moreover, the ratio of the ROR value to the 95% CI span was applied to improve the credibility of the ROR. The median values of time from vaccination to onset (TTO) for the three vaccines were analyzed. Results: Compared with BNT162b2 and mRNA-1273, Ad26.COV2.S vaccination was associated with a lower death frequency (p < 0.05). Ad26.COV2.S vaccination was associated with a lower birth defect and emergency room visit frequency than BNT162b2 (p < 0.05). There were 6,605, 830, and 2,292 vaccine recipients who suffered from COVID-19-related symptoms after vaccination with BNT162b2, Ad26.COV2.S, and mRNA-1273, respectively, including people who were infected by COVID-19, demonstrated a positive SARS-CoV-2 test, and were asymptomatic. Serious AEFI, including thromboembolism, hemorrhage, thrombocytopenia, cardiac arrhythmia, hypertension, and hepatotoxicity, were associated with all three vaccines. Cardiac failure and acute renal impairment events were associated with BNT162b2 and mRNA-1273, while seizure events were associated with BNT162b2 and Ad26.COV2.S. The median values of TTO associated with the three vaccinations were similar. Conclusion: These findings may be useful for health workers and the general public prior to inoculation, especially for patients with underlying diseases; however, the risk/benefit profile of these vaccines remains unchanged. The exact mechanism of SARS-CoV-2 vaccine-induced AEFI remains unknown, and further studies are required to explore these phenomena. Keywords: Ad26.Cov2.S; BNT162b2; COVID-19 vaccine safety; adverse events following immunization; mRNA-1273; reporting odds ratio. Copyright © 2022 Yan, Zhao, Li, Chow, Zhang, Qi, Wu, Zhong and Qiu.